Rapamune

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycystic Kidney Diseases

Conditions

Polycystic Kidney Diseases

Trial Timeline

Oct 1, 2006 → Dec 1, 2014

NCT ID

NCT00286156

About Rapamune

Rapamune is a phase 1/2 stage product being developed by Pfizer for Polycystic Kidney Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00286156. Target conditions include Polycystic Kidney Diseases.

What happened to similar drugs?

3 of 14 similar drugs in Polycystic Kidney Diseases were approved

Approved (3) Terminated (4) Active (7)

🔄Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3

🔄Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

🔄Lisinopril + Telmisartan + PlaceboMerckPhase 3

🔄Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)MerckPhase 3

✅Placebo + EverolimusNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00044720	Approved	Completed	—	Jul 1, 2005	Chronic Kidney Failure
NCT01853423	Phase 1	Completed	Oct 1, 2013	Jul 1, 2016	Facial Angiofibroma
NCT00286156	Phase 1/2	Completed	Oct 1, 2006	Dec 1, 2014	Polycystic Kidney Diseases
NCT00195481	Approved	Completed	Apr 1, 2004	Dec 1, 2005	Kidney Failure
NCT00470665	Phase 3	Completed	Aug 1, 2002	Jul 1, 2004	Renal Allograft Recipients

Competing Products

20 competing products in Polycystic Kidney Diseases

See all competitors

Product	Company	Stage	Hype Score
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	17
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	35
IVF Antagonist Protocol	Merck	Pre-clinical	22
tredaptive (nicotinic acid/ laropiprant) + placebo	Merck	Approved	43
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Phase 3	40
Gonal-f® + Long GnRH agonist + GnRH antagonist	Merck	Pre-clinical	26
Placebo + Everolimus	Novartis	Approved	43
LIK066 + Placebo	Novartis	Phase 2	35
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Everolimus + Octreotide LAR	Novartis	Phase 2	35
Atorvastatin + Placebo	Pfizer	Pre-clinical	26
Sirolimus	Pfizer	Phase 2/3	34